Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic ResponsesJonathan B. Mitchem, David G. DeNardo, Donal J. Brennan et al.|Cancer Research|2012Cited by 941
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysisMustafa Suker, Bas Groot Koerkamp, Berend R. Beumer et al.|The Lancet Oncology|2016Cited by 914
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J. Sullivan, Bob T. Li, Andrea Wang‐Gillam et al.|Cancer Discovery|2017Cited by 418
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)Dung T. Le, Elizabeth M. Jaffee, Vincent J. Picozzi et al.|Clinical Cancer Research|2019Cited by 260
Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical ModelsHua Zhong, Andrea Wang‐Gillam|PLoS ONE|2013Cited by 43